The evolving NSAID: Focus on lornoxicam

Pain Reviews

Volumn 6, Issue 4, 1999, Pages 262-278

  McCormack, Keith ^a,b  

^a Drug Research Group   (United Kingdom)

^b McCormack Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; LORNOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN SYNTHASE;

ABDOMINAL PAIN; ANOREXIA; BONE PAIN; CLINICAL RESEARCH; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HEART PALPITATION; HUMAN; LEG CRAMP; MICTURITION DISORDER; MIGRAINE; NAUSEA; NOCICEPTION; PAIN; PARESTHESIA; PRURITUS; RASH; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOMNOLENCE; SWEATING; URINE RETENTION; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0033396949     PISSN: 09681302     EISSN: None     Source Type: Journal    
DOI: 10.1191/096813099678137904     Document Type: Review

References (103)

1. Collier HOJ. The story of aspirin. In: Parnham MJ, Bruinvels J eds. Discoveries in pharmacology. Haemodynamics, hormones and inflammation. Amsterdam: Elsevier, 1984; 555-94.
2. Brune K, McCormack K. The over-the-counter use of nonsteroidal anti-inflammatory drugs and other antipyretic analgesics. In: Lewis AJ, Furst DE eds. Nonsteroidal anti-inflammatory drugs. Mechanisms and clinical uses, second edition. New York: Marcel Dekker, 1994: 97-126.
3. Haas H. History of antipyretic analgesic therapy. Am J Med 1983; 75: 1-3.
4. Watson Buchanan W, Kean WF. Current nonsteroidal anti-inflammatory drug therapy in rheumatoid arthritis, with emphasis on use in the elderly. In: Lewis AJ, Furst DE eds. Nonsteroidal anti-inflammatory drugs. Mechanisns and clinical use, second edition. New York: Marcel Dekker, 1997: 9-29.
5. Anon. Nonsteroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions. BMJ 1986; 292: 1190-91.
6. McCormack K. Some new insights into the pharmacology of nonsteroidal anti-inflammatory drugs. In: Swaynok J, Cowan A eds. Novel aspects of pain management: opioids and beyond. New York: John Wiley, 1999: 73-94.
7. Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cycloozygenase-2 in inflammation of pain. Proc Natl Acad Sci U S A 1994; 91: 12013-17.
8. Longo WE, Damore LJ, Mazuski JE, Smith GS, Penesar N, Kaminski DL. The role of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide and interleukin-1 stimulated enterocyte prostanoid formation. Med Inflamm 1998; 7: 85-91.
9. Hay CH, Trevethick MA, Wheeldon A, Bowers JS, De Belleroche JS. The potential role of spinal cord cyclooxygenase-2 in the development of Freund's complete adjuvant-induced changes in hyperalgesia and allodynia. Neuroscience 1997; 78: 843-50.
10. Wallace JL. Selective COX-2 inhibitors: is the water becoming muddy? Trends Pharmacel Sci 1999; 20: 4-6.
11. Wallace JL, Chapman K, McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 1999; 126: 1200-204.
12. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5: 698-701.
13. Silas S, Clegg DO. Selective COX-2 inhibition. Bull Rheum Dis 1999; 48: 1-4.
14. Fenner H. Comparative biochemical pharmacology of the oxicams. Scand J Rheum 1987; (suppl 65): 97-101.
15. Dehouck M-P, Jolliet-Riant P, Brée F, Fruchart J-C, Cecchilli R, Tillement J-P. Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem 1992; 58: 1790-97.
16. Balfour JA, Fitton A, Barradell LB. Lornoxicam: a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51: 639-57.
17. Lombardino JG. Medicinal chemistry of acidic nonsteroidal antiinflammatory drugs. In: Lombardino JG ed. Nonsteroidal anti-inflammatory drugs. New York: John Wiley, 1985: 253-431.
18. Hansch C, Leo A. The Pomona College Medicinal Chemistry Project. Claremont, CA: Pomona College, 1983.
19. Tsai R-S, Carrupt P-A, El Tayar N, Giroud Y, Andrade P, Testa B. Physicochemical and structural properties of non-steroidal anti-inflammatory oxicams. Helv Chim Acta 1993; 76: 842-54.
20. Albengres E, Urien S, Barre J et al. Clinical pharamacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity. Int J Tiss React 1993; XV: 125-34.
21. Rainsford KD. Toxicity of currently used antiinflammatory and antirheumatic drugs. In: Lewis AJ, Furst DE eds. Nonsteroidal anti-inflammatory drugs. Mechanisms and clinical use, second edition. New York: Marcel Dekker, 1997: 215-44.
22. Buritova J, Besson J-M. Dose-related anti-inflammatory/analgesic effects of lornoxicam: a spinal c-Fos protein study in the rat. Inflamm Res 1998; 47: 18-25.
23. Doyle CA, Palmer JA, Munglani R, Hunt SP. Molecular consequences of noxious stimulation. In: Borsook D ed. Molecular neurobiology of pain (Progress in pain research and management, vol. 9). Seattle: IASP Press, 1997: 145-70.
24. Morgan JI, Curran T. Immediate-early genes: ten years on. Trends Neurosci 1995; 18: 66-67.
25. Hughes P, Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated expression within the nervous system. Pharmacol Rev 1995; 47: 133-78.
26. Zieglgänsberger W, Tölle TR. The pharmacology of pain signalling. Curr Opin Neurobiol 1993; 3: 611-18.
27. Abbadie C, Honoré P, Besson J-M. Postsynaptic changes during sustained primary afferent fibre stimulation as revealed by c-Fos immunohistochemistry in the rat spinal cord. In: Urban L, Dray A, Jeftinija S, Reeh P, Woolf CJ eds. The cellular mechanisms of sensory processing. Berlin: Laszlo Urban, 1994: 449-71.
28. Munglani R, Hunt SP. Molecular biology of pain. Br J Anaesth 1995; 75: 186-92.
29. Buritova J, Honoré P, Besson J-M. Ketoprofen produces profound inhibition of spinal c-Fos protein expression resulting from an inflammatory stimulus but not from noxious heat. Pain 1996; 67: 379-89.
30. Honoré P, Buritova J, Besson J-M. Carrageenin-evoked c-Fos expression in rat lumbar spinal cord: the effects of indomethacin. Eur J Pharmacol 1995; 272: 249-59.
31. Buritova J, Honoré P, Chapman V, Besson J-M. Concurrent reduction of inflammation and spinal Fos-LI neurons by systemic diclofenac in the rat. Neurosci Lett 1995; 188: 175-78.
32. Buritova J, Chapman V, Honoré P, Besson J-M. Interactions between NMDA and prostaglandin receptor-mediated events in model of inflammatory nociception. Eur J Pharmacol 1996; 303: 91-100.
33. Futaki N, Takahashi S, Kitigawa T, Yamakawa Y, Tanaka M, Higuchi S. Anti-inflammatory, analgesic, antipyretic and cyclooxygenase inhibitory effects of a non-steroidal anti-inflammatory agent, lornoxicam. Jpn Pharmacol Ther 1997; 25: 55-71.
34. McCormack K. Mathematical model for assessing risk of gastrointestinal reaction to NSAIDs. In: Rainsford KD ed. Azapropazone, 20 years of clinical use. Lancaster, UK: Kluwer, 1989: 81-94.
35. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14.
36. Nordone F, Staibano S, Rocco A et al. Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. Gut 1999; 44: 789-99.
37. Mohammed S, Croom DW. Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor. N Engl J Med 1999; 340: 2005-2006.
38. Kishimoto Y, Wada K, Nakamoto K et al. Quantitative analysis of cyclooxygenase-2 gene expression on acute gastric injury induced by ischemia-reperfusion in rats. Life Sci 1997; 60: 127-33.
39. Fassbender HG. The significance of inflammatory processes in osteoarthritis. Z Rheumatol 1983; 42: 145-52.
40. Shiozawa S, Tokuhisa L. Contribution of synovial mesenchymal cells to the pathogenesis of rheumatoid arthritis. Semin Arthritis Rheum 1992; 21: 267-73.
41. Dayer JM, Krane SM, Russell RG, Robinson DR. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci U S A 1976; 73: 945-49.
42. Chin JR, Murphy G, Werb Z. Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization and substrates. J Biol Chem 1985; 260: 12367-76.
43. He CS, Wilhelm SM, Pentland AP et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A 1989; 86: 2632-36.
44. Kumkumian GK, Lafyatis R, Remmers EF, Case JP, Kim SJ, Wilder RL. Platelet-derived growth factor and IL-1 interactions in rheumatoid arthritis. Regulation of synoviocyte proliferation, prostaglandin production, and collagenase transcription. J Immunol 1989; 143: 833-37.
45. Lin AH, Bienkowski MJ, Gorman RR. Regulation of prostaglandin H synthase mRNA levels and prostaglandin biosynthesis by platelet-derived growth factor. J Biol Chem 1989; 264: 17379-83.
46. Hamilton JA, Butler DM, Stanton H. Cytokine interactions promoting DNA synthesis in human synovial fibroblasts. J Rheumatol 1994; 21: 797-803.
47. Stürzebecher S, Haberey M, Müller B et al. Pharmacological profile of a novel carbacyclin derivative with high metabolite stability and oral activity in the rat. Prostaglandins 1986; 31: 95-109.
48. 2-analogues on PDGF-release and aggregation of human gelfiltered platelets. In: Schrör K, Singzinger H eds. Prostaglandins in clinical research: cardiovascular system. New York: Liss, 1989: 365-69.
49. Takacs E, Jellinek H. Early morphological changes of vessels in an experimental model system. Int Angiol 1987; 6: 7-19.
50. Willis AL, Smith DL, Vigo C et al. Orally active prostacyclin-mimetic RS-93427: therapeutic potential in vascular occlusive disease associated with atherosclerosis. In: Samuelson B, Paoletti R, Ramwell W eds. Advances in prostaglandin, thromboxane, and leukotriene research. New York: Raven, 1987: 254-265.
51. Yaron M, Djaldetti M. Platelets in synovial fluid [Letter]. Arthritis Rheum 1978; 21: 607-608.
52. Endresen GK. Investigation of blood platelets in synovial fluid from patients with rheumatoid arthritis. Scand J Rheumatol 1981; 10: 204-208.
53. Endresen GK. Demonstration of fibronectin associated with platelets in synovial fluid from patients with rheumatoid arthritis. Scand J Rheumatol 1984; 13: 351-56.
54. Endresen GKM. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1989; 9: 9-24.
55. Farr M, Scott DL, Constable T, Hawker R, Hawkins CF. Platelets and rheumatoid arthritis. Ann Rheum Dis 1981; 40: 617-18.
56. Farr M, Wainwright A, Salmon M, Hollywell CA, Bacon PA. Platelets in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 1984; 4: 3-17.
57. De Gaetano G, Cerletti C, Nanni-Costa MP, Poggi I. The blood platelet as an inflammatory cell. Eur Respir J 1989; 2: 441s-45s.
58. Endresen GKM, Førre Ø. Human platelets in synovial fluid. A focus on the effects of growth factors on the inflammatory responses in rheumatoid arthritis. Clin Exp Rheumatol 1992; 10: 181-87.
59. Uhlin-Hansen L, Longvoll D, Wik T, Kalset SO. Blood platelets stimulate the expression of chondroitin sulfate proteoglycan in human monocytes. Blood 1992; 80: 1058-65.
60. Ertenlin I, Haznedaroglu IC, Kiraz S, Celik I, Calguneri M, Kirazhi S. Cytokines affecting megakaryocytopoiesis in rheumatoid arthritis with thrombocytosis. Rheumatol Int 1996; 16: 5-8.
61. 2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol 1996; 23: 1162-66.
62. Mannaioni PF, Bi Bello G, Masini E. Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res 1997; 46: 4-18.
63. Guerne PA, Vischer TL. L'interleukine-6, parmi les autres cytokines, dans les rheumatismes. Med Hyg 1991; 49: 869-73.
64. Remmers EF, Sano H, Lafyatis R et al. Production of platelet derived growth factor B chain (PDGF-B/ c-sis) mRNA and immunoreactive PDGF B-like polypeptide by rheumatoid synovium: coexpression with heparin binding acidic fibroblast growth factor-1. J Rheumatol 1991; 18: 7-13.
65. Remmers EG, Sano H, Wilder RL. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 1991; 21: 191-99.
66. Reuterdahl C, Tingstrom A, Terracio L, Funa K, Heldin CH, Rubin K. Characterization of platelet-derived growth factor beta-receptor expressing cells in the vasculature of human rheumatoid synovium. Lab Invest 1991; 64: 321-29.
67. Ridderstadt A, Abedi-Valugerdi M, Möller E. Cytokines in rheumatoid arthritis. Ann Med 1991; 23: 219-23.
68. Smith RJ, Justen JM, Sam LM et al. Platelet-derived growth factor potentiates cellular responses of articular chondrocytes to interleukin-1. Arthritis Rheum 1991; 34: 697-706.
69. Thornton SC, Por SB, Penny R, Richter M, Shelley L, Breit N. Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor-alpha. Clin Exp Immunol 1991; 86: 79-86.
70. Goddard DH, Grossman SL, Newton R, Clark MA, Bomalaski JS. Regulation of synovial cell growth: basic fibroblast growth factor synergizes with interleukin 1 beta stimulating phospholipase A2 enzyme activity, phospholipase A2 activity protein production and release of prostaglandin E2 by rheumatoid arthritis synovial cells in culture. Cytokine 1992; 4: 377-84.
71. Harvey AK, Stack ST, Chandrasekhar S. Differential modulation of degradative and repair responses of interleukin-1-treated chondrocytes by platelet-derived growth factor. Biochem J 1993; 292: 129-36.
72. Monier S, Rème T, Cognot C et al. Growth factor activity of IL-6 in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 1994; 12: 595-602.
73. Ohba T, Takase W, Ohhara M, Kasukawa R. Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor. J Rheumatol 1996; 23: 1505-11.
74. Lemaire R, Huet G, Zerimech F et al. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br J Rheumatol 1997; 36: 735-43.
75. Schaible HG, Grubb BD. Afferent and spinal mechanisms of joint pain. Pain 1993; 55: 5-54.
76. Pruss TP, Stroißnig H, Radhofer-Welte S et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J 1990; 66: S18-S21.
77. Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D. Pharmacokinetics of lornoxicam in man. Postgrad Med J 1990; 66: S22-S26.
78. Berry H, Ollier S. Lornoxicam in clinical practice. Postgrad Med J 1990; 66: S41-S45.
79. Blackham A, Burns JW, Farmer JB, Radziwonik H, Westwick J. An X-ray analysis of adjuvant arthritis in the rat. The effect of prednisolone and indomethacin. Agents Actions 1977; 7: 145-51.
80. Engelhardt G, Homma D, Schnitzler C. Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 1995; 44: 548-55.
81. Aota S, Nakamura T, Suzuki K et al. Effects of indomethacin administration on bone turnover and bone mass in adjuvant-induced arthritis in rats. Calcif Tissue Int 1996; 59: 385-91.
82. Yamamoto N, Sakai F, Yamazaki H, Kawai Y, Nakahara K, Okuhara M. Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats. J Rheumatol 1996; 23: 1778-83.
83. Awouters F, Niemeggers CJE, Lenaerts FM, Janssen PAJ. The effects of suprofen in rats with mycobacterium butyricum-induced arthritis. Arzneimittelforschung 1975; 25: 1526-37.
84. Rainsford KD. The mode of action of azapropazone in relation to its therapeutic actions in rheumatic conditions and its major side-effects. In: Rainsford KD ed. Azapropazone, 20 years of clinical use. Lancaster: Kluwer, 1989: 31-52.
85. Lussier A, de Medicis R. Correlation between ossification and inflammation using a rat experimental model. J Rheumatol 1983; 10 (Suppl 11): 114-17.
86. Ferdinandi ES, Cayen MN, Pace-Asciak C. Disposition of etodolac, other anti-inflammatory pyranoindole-1-acetic acids and furobufen in normal and adjuvant arthritic rats. J Pharmacol Exp Ther 1982; 220: 417-26.
87. Graeme ML, Fabry E, Sigg EB. Mycobacterial adjuvant periarthritis in rodents and its modification by anti-inflammatory agents. J Pharmacol 1966; 153: 373-80.
88. Liyanage SP, Currey HL. Failure of oral D-penicillamine to modify adjuvant arthritis or immune response in the rat. Ann Rheum Dis 1972; 31: 521-23.
89. Lewis AJ, Cottney J, White DD et al. Action of gold salts in some inflammatory and immunological models. Agents Actions 1980; 10: 63-77.
90. Carlson RP, Datko LJ, O'Neill-Davis L et al. Comparison of inflammatory changes in established type II collagen-and adjuvant-induced arthritis using outbred Wistar rats. Int J Immunopharmacol 1985; 7: 811-26.
91. Garrett IR, Whitehouse MW, Vernon Roberts B, Brooks PM. Ambivalent properties of gold drugs in adjuvant induced polyarthritis in rats. J Rheumatol 1985; 12: 1079-82.
92. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs - differences and similarities. N Engl J Med 1991; 324: 1716-25.
93. Staunstrup H, Ovesen J, Larsen UT, Elbæk K, Larsen U, Krøner K. Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain. J Clin Pharmacol 1999; 39: 1-8.
94. Raffa RB, Friderichs E. The basic science aspect of tramadol hydrochloride. Pain Rev 1996; 3: 249-71.
95. Friderichs E, Reimann W, Selve N. Contribution of both enantiomers to antinociception of the centrally acting analgesic tramadol [Abstract]. Naunyn Schmiedebergs Arch Pharmacol 1992; 346 (Suppl 1): R36.
96. Hennies H-H, Friderichs E, Wilsmann K, Flohé L. Effect of the opioid analgesic tramadol on inactivation of norepinephrine and serotonin. Biochem Pharmacol 1982; 31: 1654-55.
97. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopiod components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-85.
98. Mattia A, Vanderah T, Raffa RB, Vaught TL, Tallarida RJ, Porreca F. Characterization of the unusual antinociceptive profile of tramadol in mice. Drug Dev Res 1993; 28: 176-82.
99. Raffa RB, Friderichs E, Reimann W et al. Complementary and synergistic antinociceptive interaction between the enamtiomers of tramadol. J Pharmacol Exp Ther 1993; 267: 331-40.
100. Market Dynamics: Global opportunities in pain to 2010, In: Datamonitor Healthcare Reports. London: Data monitor Publications Limited, 1998: 1-135.
101. Nørholt SE, Sindet-Pedersen S, Larsen U et al. Pain control after dental surgery: a double-blind randomised trial of lornoxicam versus morphine. Pain 1996; 67: 335-43.
102. Ilias W, Jansen M. Pain control after hysterectomy: an observer-blind, randomised trial of lornoxicam versus tramadol. Br J Clin Pract 1996; 50: 197-202.
103. Besson JM. Chronic pain models: an overview. Presented at 'New Directions in the Control of Pain' symposium. London: National Heart and Lung Institute, 1997.